Folgen
Toby Michael Maher
Toby Michael Maher
Keck Medicine of University of Southern California
Bestätigte E-Mail-Adresse bei usc.edu - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
L Richeldi, RM Du Bois, G Raghu, A Azuma, KK Brown, U Costabel, ...
New England Journal of Medicine 370 (22), 2071-2082, 2014
47482014
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline
G Raghu, M Remy-Jardin, L Richeldi, CC Thomson, Y Inoue, T Johkoh, ...
American Journal of Respiratory and Critical Care Medicine 205 (9), e18-e47, 2022
17022022
Nintedanib for systemic sclerosis–associated interstitial lung disease
O Distler, KB Highland, M Gahlemann, A Azuma, A Fischer, MD Mayes, ...
New England Journal of Medicine 380 (26), 2518-2528, 2019
15052019
Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report
HR Collard, CJ Ryerson, TJ Corte, G Jenkins, Y Kondoh, DJ Lederer, ...
American journal of respiratory and critical care medicine 194 (3), 265-275, 2016
13732016
Interstitial lung disease in systemic sclerosis: a simple staging system
NSL Goh, SR Desai, S Veeraraghavan, DM Hansell, SJ Copley, ...
American journal of respiratory and critical care medicine 177 (11), 1248-1254, 2008
13212008
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
TE Fingerlin, E Murphy, W Zhang, AL Peljto, KK Brown, MP Steele, ...
Nature genetics 45 (6), 613-620, 2013
8582013
Pulmonary fibrosis secondary to COVID-19: a call to arms?
P Spagnolo, E Balestro, S Aliberti, E Cocconcelli, D Biondini, ...
The Lancet Respiratory Medicine 8 (8), 750-752, 2020
5992020
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
TM Maher, TJ Corte, A Fischer, M Kreuter, DJ Lederer, M Molina-Molina, ...
The lancet Respiratory medicine 8 (2), 147-157, 2020
5932020
The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis
PL Molyneaux, MJ Cox, SAG Willis-Owen, P Mallia, KE Russell, ...
American journal of respiratory and critical care medicine 190 (8), 906-913, 2014
5562014
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised …
AU Wells, KR Flaherty, KK Brown, Y Inoue, A Devaraj, L Richeldi, T Moua, ...
The lancet Respiratory medicine 8 (5), 453-460, 2020
5042020
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
TM Maher, AU Wells, GJ Laurent
European Respiratory Journal 30 (5), 835-839, 2007
4292007
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
P Spagnolo, JA Kropski, MG Jones, JS Lee, G Rossi, T Karampitsakos, ...
Pharmacology & therapeutics 222, 107798, 2021
4032021
Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes
TL Reddy, M Tominaga, DM Hansell, J von der Thusen, D Rassl, ...
European Respiratory Journal 40 (2), 377-385, 2012
4012012
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury
CJ Scotton, MA Krupiczojc, M Königshoff, PF Mercer, YCG Lee, ...
The Journal of clinical investigation 119 (9), 2550-2563, 2009
3902009
Global incidence and prevalence of idiopathic pulmonary fibrosis
TM Maher, E Bendstrup, L Dron, J Langley, G Smith, JM Khalid, H Patel, ...
Respiratory research 22, 1-10, 2021
3882021
Short‐term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis
NS Goh, RK Hoyles, CP Denton, DM Hansell, EA Renzoni, TM Maher, ...
Arthritis & rheumatology 69 (8), 1670-1678, 2017
3452017
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study
RG Jenkins, JK Simpson, G Saini, JH Bentley, AM Russell, R Braybrooke, ...
The lancet Respiratory medicine 3 (6), 462-472, 2015
3262015
Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease?
AJ Byrne, TM Maher, CM Lloyd
Trends in molecular medicine 22 (4), 303-316, 2016
3242016
PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production
LJ Celada, JA Kropski, JD Herazo-Maya, W Luo, A Creecy, AT Abad, ...
Science translational medicine 10 (460), eaar8356, 2018
3102018
Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study
RJ Allen, J Porte, R Braybrooke, C Flores, TE Fingerlin, JM Oldham, ...
The Lancet respiratory medicine 5 (11), 869-880, 2017
3002017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20